Intense immune suppression for systemic lupus - The role of hematopoietic stem cells

Richard K. Burt*, Alberto Marmont, James Schroeder, Robert Rosa, Ann E. Traynor

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

17 Scopus citations


The treatment of severe autoimmune diseases has been recently revitalized by the introduction of intense immune suppression with immune ablative intent followed by three different procedures. These are allogeneic hematopoietic stem cell transplantation (HSCT), autologous HSCT (using either marrow or peripheral blood), and intense immune suppression without stem cell support. Current trials suggest that high dose immune suppressive therapy with or without autologous hematopoietic stem cell support can induce remission of previously refractory disease. Follow-up is too brief to determine if intense immune suppression, and more specifically autologous HSCT, will ultimately cure SLE. It is conceivable that an allogeneic source of stem cells from a normal donor (e.g. HLA matched sibling) will be required to achieve a cure. It is also possible that autologous HSCT, even if not curative, may prolong the life of patients with otherwise high-risk features. In carefully selected patients, the potential benefits of this procedure may outweigh the risks.

Original languageEnglish (US)
Pages (from-to)31-37
Number of pages7
JournalJournal of Clinical Immunology
Issue number1
StatePublished - 2000


  • Hematopoietic stem cell transplantation
  • Immune suppression
  • Systemic lupus

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology


Dive into the research topics of 'Intense immune suppression for systemic lupus - The role of hematopoietic stem cells'. Together they form a unique fingerprint.

Cite this